Cargando…

Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment‐Resistant Epilepsy

In patients with treatment‐resistant epilepsy (TRE), cannabidiol (CBD) produces variable improvement in seizure control. Patients in the University of Alabama at Birmingham CBD Expanded Access Program (EAP) were enrolled in the genomic study and genotyped using the Affymetrix Drug Metabolizing Enzym...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davis, Brittney H., Beasley, T. Mark, Amaral, Michelle, Szaflarski, Jerzy P., Gaston, Tyler, Perry Grayson, Leslie, Standaert, David G, Bebin, E. Martina, Limdi, Nita A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530979/ https://www.ncbi.nlm.nih.gov/pubmed/34464454 http://dx.doi.org/10.1002/cpt.2408

Ejemplares similares

Final analysis of potential drug–drug interactions between highly purified cannabidiol and anti‐seizure medications in an open‐label expanded access program
por: Gaston, Tyler E., et al.
Publicado: (2023)

A preliminary study of the effects of cannabidiol (CBD) on brain structure in patients with epilepsy
por: Sharma, Ayushe A., et al.
Publicado: (2019)

Evaluation of population‐level pharmacogenetic actionability in Alabama
por: Davis, Brittney H., et al.
Publicado: (2021)

An interaction between warfarin and cannabidiol, a case report
por: Grayson, Leslie, et al.
Publicado: (2017)

Warfarin Pharmacogenetics: Challenges and Opportunities for Clinical Translation
por: Limdi, Nita A.
Publicado: (2012)

Pharmacogenetic actionability and medication prescribing in people with cystic fibrosis
por: Anderson, Justin D., et al.
Publicado: (2023)

Long‐term safety and treatment effects of cannabidiol in children and adults with treatment‐resistant epilepsies: Expanded access program results
por: Szaflarski, Jerzy P., et al.
Publicado: (2018)

Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy
por: Klotz, Kerstin A., et al.
Publicado: (2019)

Cannabidiol in the Treatment of Epilepsy
por: von Wrede, Randi, et al.
Publicado: (2021)

Scalp EEG spikes predict impending epilepsy in TSC infants: A longitudinal observational study
por: Wu, Joyce Y., et al.
Publicado: (2019)

Epilepsy and Neurodegeneration: A Bidirectional Relationship
por: Szaflarski, Jerzy P.
Publicado: (2021)

Cannabidiol as a treatment for epilepsy
por: Pickrell, William O., et al.
Publicado: (2017)

Cannabidiol in epilepsy: The indications and beyond
por: Ryan, Melody
Publicado: (2020)

Validation of the Spartan RXCYP2C19 Genotyping Assay Utilizing Blood Samples
por: Davis, Brittney H., et al.
Publicado: (2019)

A “Sodium Drug” for Generalized Epilepsy? A Mystery That Still Needs to be Solved
por: Szaflarski, Jerzy P.
Publicado: (2021)

Don’t Fear the Reefer—Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy
por: Perry, M. Scott
Publicado: (2019)

Cannabidiol Treatment for Refractory Epilepsies in Pediatrics
por: Raucci, Umberto, et al.
Publicado: (2020)

White Matter Abnormalities in Patients with Treatment-Resistant Genetic Generalized Epilepsies
por: Szaflarski, Jerzy P., et al.
Publicado: (2016)

Seizure control in patients with epilepsy: the physician vs. medication factors
por: Szaflarski, Jerzy P, et al.
Publicado: (2008)

Pharmacogenetics of Drug-Resistant Epilepsy (Review of Literature)
por: Smolarz, Beata, et al.
Publicado: (2021)

Cannabidiol and epilepsy in Brazil: a current review
por: Oshiro, Carlos André, et al.
Publicado: (2022)

Post-traumatic epilepsy: current and emerging treatment options
por: Szaflarski, Jerzy P, et al.
Publicado: (2014)

Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy
por: Wheless, James W., et al.
Publicado: (2019)

Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs
por: Patsalos, Philip N., et al.
Publicado: (2020)

Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial
por: Thiele, Elizabeth A., et al.
Publicado: (2021)

Cannabidiol for epilepsy (Lennox-Gastaut syndrome, Dravet syndrome)
Publicado: (2020)

Challenges and recommendations for conducting epidemiological studies in the field of epilepsy pharmacogenetics
por: Grover, Sandeep, et al.
Publicado: (2011)

Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials
por: Silvestro, Serena, et al.
Publicado: (2019)

Cannabidiol for Treatment of Childhood Epilepsy–A Cross-Sectional Survey
por: Klotz, Kerstin A., et al.
Publicado: (2018)

Cannabidiol in the Treatment of Epilepsy: A Focused Review of Evidence and Gaps
por: Silva, Guilherme Diogo, et al.
Publicado: (2020)

Cannabidiol as a Modulator of the Development of Alcohol Tolerance in Rats
por: Szulc, Michał, et al.
Publicado: (2023)

Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy?
por: Koo, Chung Mo, et al.
Publicado: (2017)

Cannabidiol for the treatment of refractory epilepsy in children: a critical review of the literature
por: Moreira, Gabriela Araujo, et al.
Publicado: (2022)

Cannabidiol in the acute phase of febrile infection‐related epilepsy syndrome (FIRES)
por: Fetta, Anna, et al.
Publicado: (2023)

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real‐World Setting
por: Cavallari, LH, et al.
Publicado: (2017)

An exploratory study of brain temperature and choline abnormalities in temporal lobe epilepsy patients with depressive symptoms
por: Oates, Mina, et al.
Publicado: (2023)

Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial
por: Thiele, Elizabeth A., et al.
Publicado: (2020)

Is cannabidiol a drug acting on unconventional targets to control drug‐resistant epilepsy?
por: Rocha, Luisa, et al.
Publicado: (2020)

Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program
por: Contin, Manuela, et al.
Publicado: (2021)

A Volumetric Absorptive Microsampling Technique to Monitor Cannabidiol Levels in Epilepsy Patients
por: Dubois, Sara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b3v8jfv35ou7m6ebh3ddmt8a9u